ORN Spring 2026: Medetomidine Impacts on Clinical Management and Systems of Care-Slides - ORN Spring 2026

Slides - ORN Spring 2026 - Lynch, MD

Pdf Summary

This presentation reviewed the emergence of medetomidine, a veterinary alpha-2 agonist, as an increasingly common illicit opioid adulterant in the U.S. drug supply, with rising detection in drug-checking and public health data. Medetomidine is highly selective for alpha-2 receptors and has pharmacologic effects that can produce sedation, bradycardia, hypotension, and respiratory depression, often alongside fentanyl or other opioids.<br /><br />Clinically, medetomidine intoxication often persists after naloxone reverses opioid effects, leaving prolonged sedation, miosis, sinus bradycardia, and variable blood pressure changes. Management is largely supportive: naloxone should still be given for co-occurring opioid toxicity, most patients need oxygen and IV fluids, and pressors or ventilation are only occasionally required. Atipamezole is not recommended for human use.<br /><br />A major focus was medetomidine withdrawal, which is distinct from classic opioid withdrawal. It can begin rapidly, often within hours, and may cause severe nausea and vomiting, marked tachycardia, severe hypertension, diaphoresis, tremor, myoclonic jerks, delirium, metabolic acidosis, elevated lactate, hypokalemia, QTc prolongation, myocardial injury, and sometimes PRES. Most severe cases require ICU-level care.<br /><br />Recommended treatment emphasizes early and aggressive alpha-2 agonist therapy. Mild to moderate withdrawal may respond to clonidine or guanfacine; severe or refractory cases may require dexmedetomidine infusion followed by tapering to oral alpha-2 agonists. Supportive care includes fluids, antiemetics, electrolyte correction, and treatment of co-occurring syndromes such as opioid withdrawal or possible GABA-agonist withdrawal. Buprenorphine or methadone may still be needed, but standard COWS-based assessment may be unreliable.<br /><br />The presentation concluded that clinicians and systems must adapt quickly to evolving adulterants through suspicion, observation, multidisciplinary coordination, harm reduction, and expanded access to substance use treatment.

Keywords

medetomidine

opioid adulterant

alpha-2 agonist

naloxone

sedation

bradycardia

withdrawal

dexmedetomidine

clonidine

harm reduction